AzTrials
AzTrials

Acute Hydrocarbon ToxicityNCT06151301

Evaluation of the Role of Poisoning Severity Score, Serum Procalcitonin and C-reactive Protein in Acute Hydrocarbon Intoxicated Cases Admitted to the Poison Control Center Ain Shams University Hospitals

An observational study of Acute Hydrocarbon Toxicity, run by Sohag University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Hydrocarbons are a primary energy source in modern society. They are present in many common household and occupational products, including motor fuels, paint thinners, cleaning agents, lotions, and industrial solvents. Unfortunately, these products are also used as agents of abuse and typically inhaled . Read more about this study

Who is it for?
Any age
Conditions the study is for
Acute Hydrocarbon Toxicity
What is being tested?
serum procalcitonin and C-reactive protein
How many people
60 participants
Where
1 siteEgypt
Study dates
1 Dec 2023to 1 Dec 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Patients of both sexes admitted to the Poison control center, Ain Shams university hospitals with acute hydrocarbon toxicity during the duration from December 2023 till December 2024 with a maximum number of 60 cases within 24 hours of intoxication

Who may be able to join

  • Patients of both sexes admitted to the Poison control center, Ain Shams university hospitals with acute hydrocarbon toxicity during the duration from December 2023 till December 2024 with a maximum number of 60 cases within 24 hours of intoxication.

Who cannot join

  • Patients with these criteria will be excluded:
  • Cases > 24 hours of intoxication.
  • Cases with occupational exposure to hydrocarbons.
  • Pregnant females.
  • Any cases received any treatment before arrival to the PCC.
  • Cases suffering from cardiac, respiratory, renal, hepatic or haematological disorders.
  • Cases presenting with fever.
  • Cases with other causes that can increase levels of CRP \& pro-calcitonin as bacterial infection, recent major trauma, major burn ,septic shock and medullary thyroid cancer.

Trial locations and contacts

1 site in 1 country.

Mera G Khalil, assistant lecutrer contact

01229185948

Mera_Sadek@med.sohag.edu.eg

Maha A Helal, professor contact

Egypt1 site
  • Ain Shams university Hospital

    Cairo

    Gehan B Azab, professor

Other trials in Egypt

About this study

Hydrocarbons are a primary energy source in modern society. They are present in many common household and occupational products, including motor fuels, paint thinners, cleaning agents, lotions, and industrial solvents. Unfortunately, these products are also used as agents of abuse and typically inhaled .

They are derived mainly from petroleum (kerosene, gas, naphtha) or wood (turpentine, pine oil). They can be found in liquid, gas, or solid form depending on their properties. All hydrocarbons can be toxic, but aromatic (ring-shaped) and halogenated hydrocarbons typically have more severe toxicity .

Toxicity occurs in various ways including through inhalation, ingestion, aspiration, and dermal exposure. Frequently, these exposures occur during attempted recreational use of the substances and sometimes for self-injurious behavior

Being tested
serum procalcitonin, C-reactive protein

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • serum procalcitoninDiagnostic test

    predicting the severity of intoxication

  • C-reactive proteinDiagnostic test

    predicting the severity of intoxication

Study groups in NCT06151301
Study groupRoleWhat they receive
control group20 subjects of apparently healthy persons for estimating the standard levels of the tested biomarkers.
Receives: Diagnostic Test: serum procalcitonin; Diagnostic Test: C-reactive protein
case group60 patients divided into mild, moderate and severe toxicity according to the poisoning severity score.
Receives: Diagnostic Test: serum procalcitonin; Diagnostic Test: C-reactive protein

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Serum procalcitonin level

    measuring the level of serum procalcitonin (reference range 0-0.05µg/L)

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Nov 2023
  2. Study start1 Dec 2023 (estimated)
  3. Primary completion1 Dec 2024 (estimated)
  4. Study completion1 Dec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06151301
Sponsor's protocol ID
Soh-Med-23-11-01MD
Status last verified
Nov 2023
First submitted
21 Nov 2023
Last updated
30 Nov 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Hydrocarbon Toxicity, run by Sohag University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 30 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Mera G Khalil, assistant lecutrer (01229185948, Mera_Sadek@med.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Serum procalcitonin level (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in